Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026

ASSEMBLY BIOSCIENCES, INC.

2026-Q1 EPS reported -$0.54 revenue$8,213,000

Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.
Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.
Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.
Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.
Cash runway projected into 2028.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.